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ABSTRACT
Acid sphingomyelinase (A-SMase) plays an important role in the initiation of CD95 
signaling by forming ceramide-enriched membrane domains that enable clustering 
and activation of the death receptors. In TNF-R1 and TRAIL-R1/R2 signaling, 
A-SMase also contributes to the lysosomal apoptosis pathway triggered by receptor 
internalization. Here, we investigated the molecular mechanism of CD95-mediated 
A-SMase activation, demonstrating that A-SMase is located in internalized CD95-
receptosomes and is activated by the CD95/CD95L complex in a biphasic manner.
Since several caspases have been described to be involved in the activation of 
A-SMase, we evaluated expression levels of caspase-8, caspase-7 and caspase-3 in 
CD95-receptosomes. The occurrence of cleaved caspase-8 correlated with the first 
peak of A-SMase activity and translocation of the A-SMase to the cell surface which 
could be blocked by the caspase-8 inhibitor IETD.
Inhibition of CD95-internalization selectively reduced the second phase of 
A-SMase activity, suggesting a fusion between internalized CD95-receptosomes 
and an intracellular vesicular pool of A-SMase. Further analysis demonstrated that 
caspase-7 activity correlates with the second phase of the A-SMase activity, whereas 
active caspase-3 is present at early and late internalization time points. Blocking 
caspases-7/ -3 by DEVD reduced the second phase of A-SMase activation in CD95-
receptosomes suggesting the potential role of caspase-7 or -3 for late A-SMase 
activation.
In summary, we describe a biphasic A-SMase activation in CD95-receptosomes 
indicating (I.) a caspase-8 dependent translocation of A-SMase to plasma membrane 
and (II.) a caspase-7 and/or -3 dependent fusion of internalized CD95-receptosomes 
with intracellular A-SMase-containing vesicles.
INTRODUCTION
CD95 is a member of the tumor necrosis factor 
receptor (TNF-R)-superfamily, and besides TNF-R1, one 
of the best characterized death receptors [1, 2]. CD95 
exists as a membrane-bound form (mCD95) as well as 
a soluble version generated by alternative splicing or 
matrix metalloproteinase (MMP) mediated shedding. The 
soluble form of CD95 receptor is believed to have anti-
apoptotic functions while the transmembrane receptor 
induces apoptosis, activation of and inflammation or acts 
as a costimulatory molecule [3–5]. Upregulation of CD95 
in tumor cells is activated by various stimuli including 
TNF-α, IFN-γ, interleukins, nitric oxide, chemotherapy 
and ionizing radiation [6].
CD95 ligand (CD95L, FasL, CD128 or TNFSF6), 
is a type-2 transmembrane glycoprotein of the TNF-
superfamily of cytokines, that activates apoptotic or 
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non-apoptotic CD95 signaling pathways [7]. Membrane 
bound CD95L (mCD95L) of activated natural killer (NK) 
cells and T-lymphocytes induces apoptosis in infected 
or transformed cells by interacting with the mCD95 
[8–10]. MMP 3, 7, 9 and ADAM-10 (a disintegrin and 
metallprotease-10) are able to shed m CD95L in different 
cellular systems releasing a soluble ligand (sCD95L) [11–
14]. The soluble form competes with m CD95L for binding 
to the receptor and induces proliferation and cell migration 
but also inflammation rather than apoptosis [15–17]. For 
its physiological activity, in its extracellular part, CD95L 
contains a domain for self-aggregation and trimerization 
[18]. Apparently, coupling of two homotrimeric sCD95L 
molecules forms a hexameric structure which is able to 
induce apoptosis instead of proliferation [19].
Binding of CD95L to CD95-receptor can induce 
apoptotic and non-apoptotic signaling cascades. The 
decision, which pathway is activated, is not fully 
understood. The non-apoptotic pathway is preferentially 
activated when caspase-8 is inhibited through high 
levels of cFLIP (cellular FLICE/caspase 8-like inhibitory 
protein), followed by the recruitment of TRAF1 (TNF 
receptor associated factor 1), TRAF2, RIP (receptor-
interacting protein) kinase and Raf-1 (rapidly accelerated 
fibrosarcoma) and resulting in ERK and NF-κB activation 
[20–22]. Apoptosis is induced by binding of the trimerized 
membrane CD95L resulting in receptor aggregation and 
a conformational change of its intracellular part [23]. 
Subsequently, the adaptor protein FADD (Fas associated 
protein with death domain) is recruited to the death 
domain (DD) of the receptor serving as a platform for 
the recruitment of caspase-8 to form the death inducing 
signaling complex (DISC). Active caspase-8 cleaves and 
activates effector caspases (e.g. caspase-3 or -7) leading to 
the induction of apoptosis [24].
In the context of CD95-mediated apoptosis 
induction, two differentially responding cell types have 
been described. In type I cells (e.g. SKW6.4, HuT78, 
ACHN), large DISCs are formed resulting in massive 
caspase-8 activation, and fast and direct induction of 
effector caspases and apoptosis. In type II cells (e.g. 
Jurkat, CEM, SR) only a small amount of DISCs are 
formed which results in less active caspase-8. To induce 
apoptosis, caspase-8 truncates Bid to form tBid which 
mediates the permeabilization of the mitochondrial 
membrane, the release of cytochrome c and the formation 
of an apoptosome [25, 26]. Active caspase-9 amplifies the 
apoptotic signal by activation of further effector caspases 
[27–29].
The internalization of CD95 is critical for apoptosis 
induction. In an early phase after ligand binding, SDS-
stable CD95-aggregates interact with actin filaments to 
form large clusters (capping). These caps then internalize 
in a clathrin-dependent manner, forming CD95-
receptosomes [30–32]. Inhibition of CD95 receptor 
internalization in type I cells results in a blockade of 
apoptosis and in induction of the ERK and NF-κB 
signaling pathways enlightening the crucial role of CD95 
receptor compartmentalization for apoptosis induction [28, 
33, 34].
The endolysosomal enzyme acid sphingomyelinase 
(A-SMase) is activated after CD95, TNF-R1 and TRAIL 
receptor stimulation and also plays an important role in 
various death signaling pathways [35–41]. A-SMase 
catalyses the hydrolysis of sphingomyelin to generate 
the pro-apoptotic second messenger ceramide. The 
enzyme can be activated by different mechanisms 
including posttranslational modifications and proteolytic 
cleavage [42–44]. We have shown that hydrolysis 
of phosphatidylcholine by phosphatidylcholine-
specific phospholipase C results in the formation of 
diacylglycerol, activating protein kinase C (PKC) and 
A-SMase [45]. Furthermore, it was demonstrated that 
PKCδ phosphorylates A-SMase at Ser508, resulting in its 
activation and translocation to the plasma membrane [46]. 
Reactive oxygen species (ROS) have also been described 
to activate A-SMase possibly by inducing dimerization of 
the protein [47–50]. Moreover, we recently have shown 
that stimulation of TNF-R1 leads to a sequential activation 
of caspase-8 and caspase-7 resulting in proteolytic 
cleavage of A-SMase to yield higher enzymatic activity 
[51].
Studies revealed that after binding of CD95L or 
agonistic APO-1 antibody, small amounts of FADD and 
caspase-8 are recruited to the receptor, leading to the 
activation and translocation of A-SMase to the plasma 
membrane [52, 53]. In this context it has been reported 
that translocation of A-SMase is a Syntaxin-4 dependent 
process [55]. Cell surface A-SMase generates ceramide 
which in turn forms membrane platforms resulting in the 
clustering of CD95 receptors. These clusters are necessary 
for the internalization of the receptor and promote CD95 
death signaling [56, 57]. The importance of A-SMase in 
the signaling cascade was demonstrated by inhibition or 
genetic deficiency of A-SMase which blocked the pro 
apoptotic CD95 signaling [38, 39, 58, 59].
So far, contribution of A-SMase to CD95 signaling 
has only been described for the first minutes after 
engagement while its importance at later time points is 
still unknown. Here, we investigated A-SMase activity 
at early and late stages of CD95 signaling to determine 
the localization and the role of A-SMase for the induction 
of apoptosis. We showed that the physiologically active 
CD95L induced A-SMase activation not only within the 
first minutes, but also at later time points in a second 
phase starting 30 minutes after CD95 stimulation. 
Immunofluorescence analyses and CD95-receptosome 
isolation indicated that A-SMase is located in such vesicles 
and is activated in a biphasic manner. The caspase-8 
inhibitor IETD blocked the first activation peak suggesting 
an initial caspase-8-dependent activation of A-SMase. 
The second phase could be blocked with the dynamin 
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inhibitor Dynasore indicating an internalization-dependent 
A-SMase activation mechanism. The caspase-3/-7 
inhibitor DEVD also blocked the second phase of 
activation. In immunofluorescence analyses, we observed 
a co-localization of internalized CD95 with caspase-3 or -7 
and their active forms. Immunoprecipitation of A-SMase 
revealed a direct interaction of pro-caspase-3 and -7 and 
the cleaved and activated caspase-7.
These present results suggest a so far unknown 
signaling pathway where internalized CD95-receptosomes 
fuse with trans-Golgi vesicles containing A-SMase, 
which in turn gets activated by caspases-3/-7 within these 
multivesicular bodies.
RESULTS
Soluble CD95L induces caspase dependent 
cell death and biphasic A-SMase induction in 
SKW6.4 cells
We investigated the biological outcome of soluble 
CD95 ligand (CD95L) treatment of SKW6.4 cells. In this 
study we used a CD95L which was N-terminally modified 
with an Fc-, Strep- and a FLAG-tag (SFF-CD95L). Figure 
1a shows the apoptosis induction after treating cells for 
6 hours with SFF-CD95L measured by FACS: After 
incubation, an increase in Annexin V positive cells from 
1.8 to 34.5% was measured and PI positive cells increased 
from 3.7 to 6.6%.
Figure 1b shows the time course of CD95L induced 
activation of the caspases-8, -7 and -3 in Western blots of 
total cell lysates.
In earlier studies, we have demonstrated that 
apoptosis induction in type I tumor cells depends on 
the induction of the ‘lysosomal-mitochondrial apoptosis 
amplification loop’ [28, 33]. We recently showed that 
in TNF-induced apoptosis, the sequential activation of 
caspases-8 and -7 lead to the activation of the lysosomal 
enzyme A-SMase. Interestingly, when we now treated 
cells with CD95L we recorded a bi-phasic activation of 
A-SMase in respective cell lysates (Figure 1c). The first 
activation peak occurred at 5 min of CD95L-treatment, 
whereas the second activation phase started after 30 min.
Soluble CD95L induces CD95 internalization in 
type I cells
In earlier studies on CD95-signaling in type I 
tumor cells and also in our previous studies on TNF-
signaling, we found that ligation of the receptor resulted 
in their internalization [33, 34, 51, 60, 61]. As shown by 
fluorescence microscopy in Figure 2a, ligand binding 
also induced CD95-internalization in HuT78 cells (upper 
panel). Pre-treatment of the cells with the dynamin 
inhibitor Dynasore blocked CD95-internalization (lower 
panel). To support these findings, we magnetically isolated 
CD95-receptosomes from CD95L-treated SKW6.4 cells 
after different time points of internalization. These type I 
cells have been selected instead of Hut78 cells because of 
the higher yield of receptosomes material. The results are 
shown in Figure 2b (left part): The first panel shows the 
enrichment of CD95 in the magnetic fractions (panel one). 
The following panels show the time dependent recruitment 
of the adaptor protein FADD (panel two) and caspase-8 
as well as its activation within receptosomes (panels 
four and five). To follow the intracellular trafficking of 
CD95-receptosomes, we analyzed the recruitment of 
clathrin and Rab4 (panels six and seven). The recruitment 
and activation of cathepsin D (panels eight and nine) 
confirmed our earlier findings of a fusion process between 
CD95-receptosomes with a lysosomal compartment, 
triggering the induction of the ‘lysosomal-mitochondrial 
apoptosis amplification loop’. The corresponding non-
magnetic fractions of these preparations are shown in the 
right panel.
A-SMase is activated in CD95-receptosomes
To investigate the spatial distribution and a possible 
interaction of CD95 and A-SMase, we then analyzed 
the subcellular localization of CD95 and A-SMase by 
confocal laser-scanning microscopy (CLSM, Figure 
3a). We observed a co-localization of both proteins 
already five minutes after ligand binding at the plasma 
membrane. Co-localization increased over time, indicating 
fusion events of CD95-receptosomes with lysosomes or 
A-SMase-carrying endosomes. To support these findings, 
we isolated CD95-receptosomes after various time points 
of internalization. Figure 3b (left panel) shows an initial 
activation of A-SMase already after 1 min of endocytosis 
initiation. The second activation phase occured 30 to 60 
min after receptor-internalization and thus, is in perfect 
accordance with the lysosomal fusion observed by 
confocal laser-scanning microscopy (see Figure 3a). Of 
note, A-SMase activation was only observed in the CD95 
magnetic fractions (receptosome preparations), but not in 
the non-magnetic residual lysate fractions, indicating that 
the activation of A-SMase is tightly linked to CD95.
The following Western blot analysis of CD95 and 
A-SMase in isolated CD95-receptosomes corroborated 
these findings (Figure 3c): A-SMase was recruited rapidly 
upon ligand binding (1 min) and 30 to 60 min after 
receptor internalization. Together, these findings clearly 
show that CD95 and A-SMase co-localize in two distinct 
subcellular compartments (plasmamembrane and endo-
lysosomes) at different time points.
Based on studies of others and on our own findings 
for TNF-signaling, we assumed that the fission of newly 
formed receptosomes from the plasma membrane (PM) is 
finished at about 3-5 min after endocytosis induction [62, 
63]. Thus, we believed that the early appearance of CD95/
A-SMase co-localization was due to the translocation of 
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Figure 1: Apoptosis inducing SFF-CD95L activates the A-SMase in SKW6.4 cell lysates in a biphasic manner. a. Induction 
of apoptosis in SKW6.4 cells after treatment with 100 ng/ml SFF-CD95L analyzed by AnnexinV/propidium iodide staining. b. Western 
blot analysis of SFF-CD95L induced activation of caspases. Initiator caspase-8 as well as effector caspases-3 or -7 showed a type I cell 
line dependent activation kinetic. c. Time course of A-SMase activity determined in SKW6.4 cell lysates after SFF-CD95L treatment. The 
activity maximums appeared after 15 and 90 minutes SFF- CD95L stimulation (n=3, 1way-Anova with Bonferroni’s multiple comparison 
test).
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A-SMase to the PM as already described by Grassmé 
and colleagues [52], while the later one required receptor 
endocytosis and fusion with a lysosomal compartment.
The first phase: A-SMase activation early after 
ligand binding is caspase-8 dependent
Previous reports suggested a role of caspase-8 in 
the internalization of CD95 upon ligand binding [31]. 
To analyse possible contribution of caspase-8 to the first 
phase of A-SMase activation, we treated cells with the 
caspase-8 inhibitor IETD before SFF- CD95L incubation 
or left them untreated and then compared CD95/A-SMase 
co-localization by CLSM. Figure 4a (upper panel) shows 
the co-localization of both molecules after 1 to 5 minutes. 
Pre-treatment with IETD prevented this co-localization 
(lower panel). In Figure 4b, we confirmed the CD95L 
triggered exposure of A-SMase to the plasma membrane 
with a maximum staining intensity after 5 min of ligand 
treatment. The analysis of A-SMase activation in isolated 
Figure 2: The SFF-CD95L induces the CD95-internalization in type I cells. a. Immunofluorescence analysis of SFF-CD95L 
induced CD95 internalization in HuT78 cells. The CD95L induced a time-dependent internalization of the CD95 receptor which is blocked 
by the dynamin-specific inhibitor Dynasore. b. Time course of intracellular CD95-receptosome trafficking (left panel) and corresponding 
non-magnetic fractions (right panel) in SKW6.4 cells. Magnetic and non-magnetic fractions derived after indicated times of CD95 
internalization were analyzed for CD95, DISC proteins (FADD and Caspase-8), clathrin (Clathrin HC), early endosomes (Rab 4A) and 
lysosomes (Cathepsin D).
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Figure 3: Biphasic activation of A-SMase in CD95-receptosomes. a. Merged confocal microscopic images of SKW6.4 cells 
stimulated with 100 ng/ml SFF-CD95L. The CD95L was visualized by an anti-FLAG antibody and anti-mouse Alexa-Fluor 488. A-SMase 
stained by a polyclonal anti-A-SMase antibody and anti-rabbit Alexa-Fluor 555 was detected in CD95-receptosomes between 1 min and 
60 min internalization. Co-localization of CD95 and A-SMase is indicated in yellow. b. Magnetic and non-magnetic fractions were used 
to measure A-SMase activation in SKW6.4 cells after indicated time points of CD95 internalization. Three independent preparations were 
pooled and measured in triplicate. (1way-Anova with Bonferroni’s multiple comparison test) c. Western blot analysis of CD95 magnetic 
and non-magnetic fractions with anti-CD95 and anti-A-SMase antibodies. Corresponding to the activity assay, Western blot analysis 
demonstrated a biphasic appearance of A-SMase in the magnetic fractions.
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Figure 4: Characterization of the first A-SMase activation peak. a. Translocation of A-SMase to the plasma membrane in non-
permeabilized SKW6.4 cells. Stimulation with 100 ng/ml SFF-CD95L resulted in a rapid translocation of A-SMase to the cell surface 
(upper panel) which was abrogated after co-treatment with 50 μM caspases-8 inhibitor IETD (lower panel). b. Transient exposure of the 
A-SMase to the plasma membrane induced by SFF-CD95L. Non-permeabilized SKW6.4 cells were stimulated for indicated time points 
with 100 ng/ml SFF-CD95L and analyzed by flow cytometry. c. Comparison of A-SMase activation in CD95 magnetic and non-magnetic 
fractions from SKW6.4 cells treated with or without IETD (50 μM). In contrast to the control, IETD blocked the first activation peak of 
A-SMase in CD95 magnetic fractions. Represented are the mean values of four independently performed assays with control cells and three 
independent experiments with IETD treated cells. (2way Anova with Bonferroni post-test) d. Western blot analysis of CD95 magnetic and 
non-magnetic fractions isolated from IETD treated SKW6.4 cells with anti-CD95, anti-A-SMase and anti-Cathepsin D antibodies.
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CD95-magnetic fractions confirmed these findings (Figure 
4c): The biphasic activation of A-SMase is apparent in 
CD95L treated cells (left side, black columns). Caspase-8 
inhibition by IETD blocked the first activation peak but 
still allowed later activation (red columns). A-SMase 
activation was not detected in the non-magnetic fractions 
(right panel). In the same magnetic and non-magnetic 
fractions, we analyzed the recruitment of pro-A-SMase 
and mature cathepsin D as a marker for the lysosomal 
compartment by Western blotting. Indeed, A-SMase 
recruitment could not be observed at the early time points 
(Figure 4d). Together, these findings implicate a crucial 
role for caspase-8 in the early A-SMase activation phase.
The second phase: Late A-SMase activation 
requires CD95 internalization
We next analyzed the intracellular CD95-trafficking 
by confocal laser-scanning microscopy in more detail. As 
detailed in Figure 5a, co-localization of CD95 with the 
early endosomal marker Rab4 was visible after15 min of 
receptor internalization. The intracellular maturation and 
fusion with trans-Golgi vesicles became apparent by the 
recruitment of Vti1b after 30 min (middle panel) and of 
Cathepsin D (CTSD) after 60 min (right panel) of CD95 
internalization.
We already described the potency of the dynamin 
inhibitor Dynasore to prevent CD95 internalization 
(Figure 2a). We isolated CD95 magnetic fractions from 
Dynasore treated SKW6.4 cells after different time points. 
Measurement of A-SMase activity in these preparations 
revealed that the first activation still occurred while 
the second phase was absent (Figure 5b, left panel, red 
columns). In contrast, isolation of receptosomes from 
non-Dynasore treated cells showed both activation phases 
(black columns). Again, no A-SMase activation was 
observed in the non-magnetic fractions. We additionally 
analyzed CD95-magnetic fractions from Dynasore treated 
cells by Western blot probing for the recruitment of pro-
A-SMase and CTSD: Both molecules were only recruited 
early after ligand binding. These findings indicate that the 
second A-SMase activation phase depended on receptor 
internalization and the subsequent fusion of receptosomes 
with the lysosomal compartment.
A-SMase activation within CD95-receptosomes 
requires caspase-3 or -7
In an earlier study, we described the requirement 
of caspase-7 for A-SMase activation in response to 
TNF [51]. Based on these observations, we next pre-
treated SKW6.4 with the caspase-3/-7 inhibitor DEVD 
and subsequently isolated CD95-receptosomes (Figure 
6a). A-SMase activity assays of these fractions revealed 
that its activation was blocked in the inhibitor treated 
cells (red columns, left panel). In untreated cells, the 
previously described biphasic activation was apparent 
(black columns). Western blot analyses of CD95 magnetic 
fractions revealed the recruitment and activation of both 
caspase-3 and -7 to CD95-receptosomes at late time points 
(Figure 6b).
Subsequent to the biochemical analysis of CD95 
magnetic fractions we performed localization analyses by 
confocal laser-scanning microscopy. Figure 6c documents 
co-localization of both, pro-caspase-7 (upper panel) and 
cleaved caspase-7 (lower panel) with SFF-CD95L bound 
to CD95. The cleavage/activation of caspase-7 appeared 
clearly following (15-60 min) its initial recruitment. We 
observed a similar co-localization of CD95 with both, pro- 
and cleaved caspase-3 (Figure 6d). These observations 
indicated that the CD95 induced A-SMase activation 
depended on the enzymatic activity of caspase-3 or -7 
and that both enzymes were recruited and activated in 
internalized CD95-receptosomes.
A-SMase interacts with caspase-3 or -7
To investigate a physical interaction between 
A-SMase and Caspase-3 or -7, we performed 
immunoprecipitation assays of A-SMase and analyzed 
co-precipitation with caspase-8, -7 and -3 (Figure 7a). 
For these experiments, we used stably eGFP-A-SMase 
overexpressing HeLa cells [51]. eGFP-A-SMase could 
be precipitated from untreated and CD95L-treated cell 
lysates (first panel). Pro-caspase-8 was constitutively 
co-precipitated but not the active form (second and 
third panel). Both, pro-caspase-7 (middle panel) and 
pro-caspase-3 (lower panel) were co-precipitated. For 
caspase-7, also the cleaved fragment was co-precipitated 
(middle panel). The constitutive interaction between 
A-SMase and caspase-3 and -7 was substantiated by 
co-localization analysis by confocal laser-scanning 
microscopy of non-stimulated SKW6.4 cells (Figure 7b).
In order to address the question of a functional 
relevance of the CD95 association with A-SMase, we 
treated immunoprecipitated A-SMase preparations 
either with recombinant active caspase-3 (Figure 7c, 
upper panel) or -7 (lower panel) or left them untreated. 
Subsequent measurement of A-SMase activity revealed 
that both enzymes induced A-SMase activation with a 
similar potency.
All in all the present results demonstrate that 
A-SMase and both caspases-3 and -7 co-localize in 
the same CD95-containing intracellular compartment, 
physically interact with each other and that both caspases 
can directly stimulate A-SMase activity.
DISCUSSION
A-SMase plays an important role in death-
receptor mediated apoptosis. For TNF-R1 signaling, 
we have shown that A-SMase is cleaved and activated 
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Figure 5: Characterization of the second A-SMase activation peak. a. Immunofluorescence analysis of the intracellular CD95 
trafficking in SKW6.4 cells. Localization analysis of SFF-CD95L/CD95 (green) with early endosomal marker Rab4A (red) or trans-Golgi 
marker Vti1b (red), and Cathepsin D. Co-localization is indicated in yellow. b. Measurement of A-SMase activation in control or Dynasore 
treated (80 μM) CD95 magnetic and non-magnetic fractions. The second activation peak of A-SMase in CD95 magnetic fractions was 
blocked by the dynamin inhibitor Dynasore. Represented are the mean values of four independently performed assays with control cells 
and two independent experiments with Dynasore treated cells. (n=2) c. Time course of CD95 internalization in magnetic and non-magnetic 
fractions isolated from Dynasore treated SKW6.4 cells. The fractions were analyzed with anti-CD95, anti-A-SMase and anti-Cathepsin D 
antibodies.
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Figure 6: Caspase-3 or -7 are responsible for the second A-SMase activation peak in CD95-receptosomes. a. A-SMase 
activity in magnetic and non-magnetic fractions isolated from control or DEVD (inhibitor of caspase-7 / -3) treated SKW6.4 cells. DEVD 
decreases the second activation peak of A-SMase in the magnetic fraction demonstrating the potential role of caspase-7 and -3 in the 
activation of the A-SMase. Represented are the mean values of four independently performed assays with control or DEVD treated cells 
(2way Anova with Bonferroni post-test). b. Western blot analysis of CD95 magnetic and non-magnetic fractions isolated from SKW6.4 
cells with anti-pro-caspase-7, anti-cleaved-caspase-7, anti-pro-caspase-3 and anti-cleaved-caspase-3 antibodies. c and d. Merged confocal 
microscopic images of SKW6.4 cells shows a co-localization (yellow) between SFF-CD95L/CD95 (green) and pro-caspase-7, cleaved-
caspase-7, pro-caspase-3 or cleaved-caspase-3 (red) at indicated times of CD95 internalization.
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Figure 7: A-SMase interacts with caspases-3 or caspases-7. a. Immunoprecipitation of A-SMase with an anti-A-SMase antibody 
from unstimulated and SFF-CD95L stimulated HeLa wild-type cell lysates. Western blots show that pro-caspase-3, pro-caspase-7 and 
cleaved-caspase-7 co-precipitates with A-SMase. b. Immunofluorescence analysis visualize a co-localization (yellow) between A-SMase 
(red) and caspases-3 or caspases-7 (green) in unstimulated SKW6.4 cells. c. Activation of immunoprecipitated A-SMase-GFP after 15 min 
incubation with caspase-3 or caspase-7 (n=3, 1way Anova with Bonferroni multiple comparison test).
Oncotarget12www.impactjournals.com/oncotarget
via a sequential proteolytic activation of caspase-8 and 
caspase-7 within TNF-R1 receptosomes [51]. For CD95 
signaling it was described that A-SMase is activated 
and translocates to the plasma membrane forming 
ceramide-enriched membrane platforms. Since the role of 
intracellular A-SMase after CD95 internalization had not 
been investigated, we analyzed the molecular mechanism 
in more detail.
Most studies on CD95 signaling have been 
performed with the agonistic antibodies APO1-3 or CH11 
[28, 40, 64, 65]. In the present work we used a CD95L 
which was N-terminally modified with an Fc-, Strep- and 
a FLAG-tag. The human IgG1 Fc region allowed the 
oligomerization of CD95L which is necessary for the 
induction of apoptosis [19]. The biological activity of the 
purified ligand was measured by the exposure of Annexin 
V on the cell surface. After 6 h of incubation, more than 
30% of the cells were already Annexin V positive. In line 
with this, the cleavage of caspase-8, -3 and -7 further 
demonstrated the SFF-CD95L-induced apoptosis. The 
biological activity of physiological CD95L has already 
been described before, however, it was still unclear if 
this ligand could induce internalization of CD95 [33, 66]. 
For this, all further analyses were performed with SFF- 
CD95L to answer this question.
Immunofluorescence analysis and Western blot 
confirmed the internalization of the CD95 after binding 
of CD95L. These results are in contrast to data obtained 
by Chaigne-Delalande and colleagues who published 
that internalization of CD95 was just detectable after 
stimulation with the agonistic antibody APO1-3 whereas 
the modified CD95L did not induce internalization of 
the receptor [64]. On the other hand, Lee and colleagues 
as well as Eramo and colleagues demonstrated that 
CD95L is able to induce CD95 receptor internalization 
[33, 66]. In the present work the CD95 internalization 
was confirmed by immunofluorescence analysis using 
the inhibitor Dynasore which blocks the fission of 
endocytotic vesicles. While the CD95L-CD95 receptor 
complex was internalized upon temperature shift to 37°C, 
Dynasore blocked this process resulting predominantly 
in cell surface localization of CD95. CD95 receptor 
internalization was described to be an actin and clathrin-
dependent process [34].
Grassmé and colleagues demonstrated that an early 
activation of A-SMase is involved in CD95 clustering [52, 
57]. In addition to early A-SMase activation, we showed 
a second activation phase occurring at 30 to 60 min in 
SFF-CD95L stimulated SKW6.4 lysates. The observed 
effects in lysates were confirmed by isolation of CD95-
receptosomes and measurement of A-SMase activity. 
Analyzing magnetic and non-magnetic fractions of CD95 
receptosomes preparations, we were able to show that 
A-SMase is activated in a biphasic manner in magnetic 
fractions whereas activity in non-magnetic fraction 
remained unchanged. Western blot analysis confirmed the 
biphasic appearance of A-SMase in the magnetic fractions. 
Immunofluorescence analysis of CD95L and A-SMase 
demonstrated that co-localization of both proteins was 
detectable already after 5 min up to 60 min. The first 
activation peak has already been described, suggesting that 
caspase-8 is involved in the activation process [52–54].
Using the caspase-8 inhibitor IETD, we were 
able to show that the first activation peak is caspase-8 
dependent. By CLSM analysis, A-SMase activity assays 
and Western blot analysis, we demonstrated that A-SMase 
translocates to the plasma membrane and that activation 
after early time points was blocked whereas the later 
activation peak was still present. These results support 
the finding by Grassmé and colleagues, that translocation 
and activation of A-SMase at the plasma membrane 
is a caspase-8-dependent process [52]. Perrotta and 
colleagues demonstrated that Syntaxin-4 is also involved 
in the translocation and activation of A-SMase after CD95 
stimulation. The translocation of A-SMase is associated 
with a fusion process of A-SMase positive lysosomes 
with the plasma membrane mediated by Syntaxin-4 
[55]. Blocking Syntaxin-4 could be a further target to 
inhibit A-SMase activation, ceramide-enriched platform 
formation and CD95 receptor internalization. Although 
the first activation peak could be blocked by IETD, the 
second activation peak remained unchanged, indicating a 
caspase-8-independent activation mechanism in that case.
Western blot analysis of magnetic fractions 
demonstrated the biphasic appearance of A-SMase 
in CD95-receptosomes correlating with an increased 
A-SMase activity. Since no increase of A-SMase 
activity was measured in non-magnetic fractions, we 
hypothesized that A-SMase is incorporated into to CD95-
receptosomes either by co-internalization from the plasma 
membrane or by fusion processes of trans-Golgi vesicles 
with internalized CD95 containing vesicles, similar as 
described by us for the TNF-R1 system [43]. The results 
obtained with the caspase-8 specific inhibitor IETD 
demonstrated a block of the first activation peak and an 
inhibition of the translocation of A-SMase. However, the 
second peak remained unchanged under these conditions, 
indicating that co-internalization does not play a role, 
since the second activation peak should have been blocked 
as well. Fusion processes with intracellular vesicles were 
already described for TNF-R1 [61, 62]. Pre-pro-CTSD 
and A-SMase carrying trans-Golgi vesicles fuse with 
the internalized TNF-R1 forming multivesicular bodies. 
During the fusion and maturation process marker proteins 
for early endosomes (Rab5), trans-Golgi vesicles (Vti1b) 
and late endosomes (Lamp-1) were found to co-localize 
with TNF-R1 [62].
The Western blot analysis of the magnetic and 
non-magnetic fractions demonstrated, that upon CD95L 
binding, proteins of the DISC (FADD and caspase-8) were 
recruited and activated. Fusion of CD95-receptosomes 
with intracellular vesicles could be observed by increased 
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amount of the endosomal marker protein Rab4A at 1 to 
15 min and endo-lysosomal protein CTSD at 30 and 60 
min of internalization. Confocal immunofluorescence 
analysis demonstrated a co-localization of CD95 receptor 
with Rab4A (15 min), Vti1b (30 min) and CTSD (60 
min). These findings confirm the results of Lee and 
colleagues and demonstrate that CD95L induces the CD95 
internalization. Similar to the TNF-R1 system, CD95 
receptosomes fuse with intracellular vesicles and form 
multivesicular bodies [33, 62].
Because A-SMase is present and activated in CD95 
receptosomes, we analyzed if internalization is required 
for the second activation peak. Therefore, Dynasore was 
used to block the internalization of the receptor. Isolation 
and analysis of CD95 magnetic fractions revealed, that 
A-SMase is not activated at the second peak in comparison 
to untreated control cells. Western blot analysis confirmed 
that the amount of A-SMase is clearly reduced at 30 and 
60 minutes of CD95 activation. Studies on internalization 
blockade demonstrated that cells are protected from cell 
death [33, 34]. CD95 receptors which were retained at the 
cell surface induce pro-survival and proliferative signaling 
cascades by activation of ERK and NF-κB. In contrast, 
CD95 internalization leads to a massive recruitment 
of DISC components to the receptor and activation of 
caspases inducing apoptosis [33, 34].
According to the obtained results, the first activation 
peak correlated with caspase-8 and the second activation 
peak with receptor internalization. However, the precise 
mechanism remains enigmatic. A-SMase can be activated 
by different mechanisms including phosphorylation, ROS 
or proteolytic cleavage [46-48, 51]. Based on mechanistic 
similarities between TNF-R1 and CD95 signaling, 
especially with regard to receptor internalization, we 
observed further parallels. According to Edelmann and 
colleagues, A-SMase is cleaved and activated by caspase-7 
Figure 8: Model of CD95L induced A-SMase activation. Biphasic activation of A-SMase in CD95-receptosomes is caused by 
two different mechanisms. CD95 ligation leads to the activation of caspase-8 which triggers a translocation of A-SMase onto the outer 
leaflet of the plasma membrane. At the plasmamembrane A-SMase colocalizes with CD95 and is supposedly involved in the formation of 
lipid rafts propagating the formation of CD95 clusters [52]. In type I cells, these receptor ligand complexes undergo clathrin-dependent 
internalization forming CD95-receptosomes. Along the endocytotic pathway CD95-receptosomes fuse with trans-Golgi vesicles (TGV) 
which contain A-SMase to form multivesicular bodies (MVB) which eventually mature to early lysosomes. Within this compartment, 
caspase-7 or caspase-3 activates A-SMase to transmit further downstream signaling.
Oncotarget14www.impactjournals.com/oncotarget
[51]. To test if other caspases than caspase-8 are involved 
in the second activation peak, we used the caspase-3/-7 
inhibitor DEVD. CD95-receptosomes isolated form 
DEVD treated SKW6.4 cells did not show any A-SMase 
activity at late but activation at early time points. Western 
blot analysis of CD95 magnetic fractions revealed the 
presence of pro-caspase-3/-7 as well as active caspase-3/-7 
in CD95-receptosomes. These findings were confirmed by 
immunofluorescence analysis showing a co-localization 
between the ligand-receptor complex and caspase-3 or 
-7 and active caspases-3 or -7, respectively. A possible 
activation mechanism of caspase-3 and -7 could be 
mediated by CTSD. Conus and colleagues demonstrated 
that CTSD is able to cleave and activate inactive caspase-8 
at acidic pH leading to homodimerisation of the caspase 
and activation of a proteolytic cascade [67]. A similar 
mechanism might be possible for A-SMase activation 
in CD95-receptosomes. Activated caspase-8 leads to a 
proteolytic cleavage of caspase-3 and -7 which in turn 
activates the A-SMase. This hypothesis was supported 
by the detection of the active form of CTSD in CD95 
receptosomes. Calpain, a Ca2+-dependent cysteine-
protease, could be a further candidate for caspase-7 
activation. It was shown, that calpain activates caspase-7 
in a caspase-8 independent manner by depolarization 
of mitochondria and the release of cytochrome c [68]. 
This mechanism could replace caspase-8 for activation 
of caspase-7 within the CD95 receptosomes and would 
support our observation that blocking of caspase-8 does 
not prevent the second activation peak of A-SMase.
How does caspase-3 and -7 enter CD95-
receptosomes? For caspase-3 it was demonstrated that 
it is located in lipid rafts at the plasma membrane [69]. 
Furthermore, the authors showed that caspase-3 is a 
component of the CD95-DISC and is necessary for a 
complete activation of caspase-8. These observations 
support the idea that caspase-3 is co-internalized with 
CD95. We revealed the presence of pro-caspase-3 and 
active caspase-3 in magnetic fractions at all time points of 
internalization, confirming a possible co-internalization. In 
contrast to caspase-3, caspase-7 was only detected after 
15 to 60 min after internalization. This late appearance 
of caspase-7, points to different mechanisms of 
incorporation compared to caspase-3. Two independent 
studies of CD95 demonstrated that upon stimulation, 
active caspase-7 was detected in microsomal fractions 
[70, 71]. Since microsomal fractions are a mixture of 
vesicles derived from the endoplasmic reticulum, Golgi 
apparatus, plasma membrane and lysosomes, the obtained 
results support the association of caspase-7 with vesicles 
and membranes. Therefore, one probable mechanism 
would be the fusion of vesicles with the internalized 
CD95-receptosomes, leading to incorporation of 
caspase-7 in these compartments. By fusion of vesicles, 
multivesicular compartments are formed where caspase-3 
and -7 are separated from A-SMase by a membrane. Slow 
acidification of the vesicles can lead to the disruption of 
the limiting membranes enabling interaction between 
the proteins. Caspase-7 is enzymatically active between 
a pH of 6.5 and 7.7 and caspase-3 between a pH of 6.4 
and 8.6 [51, 72]. This indicates that the acidification in the 
multivesicular compartments does not immediately block 
caspase activity and allows caspase-3 or -7 to cleave and 
activate A-SMase.
In order to verify an interaction between A-SMase 
and the effector-caspases-3 or -7, co-immunoprecipitation 
and immunofluorescence analyses were performed. Both 
methods demonstrated a constitutive interaction between 
A-SMase and caspase-3 or -7 in unstimulated cells. A 
similar finding had been reported by Matsumoto et al, 
showing a nitric oxide-dependent interaction of A-SMase 
and pro-caspase-3. However, this group speculated on a 
mechanism in which A-SMase protects pro-caspase-3 
from initiator-caspases induced cleavage [73]. This could 
explain the missing signal for cleaved-caspase-3 in the co-
immunoprecipitations. In case of the interaction between 
A-SMase and caspase-7 comparable results were obtained 
in our previous report [51]. However, the present findings 
also demonstrate an interaction between A-SMase and 
cleaved-caspase-7 in CD95L-stimulated cells, suggesting 
the potential role of caspase-7 for activation of A-SMase. 
These results were supported by the in vitro experiments 
where exogenous caspase-7 as well as caspase-3 activated 
precipitated A-SMase-GFP.
The results described above are schematically 
summarized in Figure 8. In conclusion, the present 
findings demonstrated a CD95L-induced biphasic 
activation of A-SMase. The earlier phase is based on the 
A-SMase translocation to the cell surface and might be 
involved in receptor endocytosis. The latter activation 
is based on CD95-receptosome/endosome/lysosome 
fusion events and is probably involved in the lysosomal-
mitochondrial apoptosis induction.
MATERIALS AND METHODS
Chemicals and inhibitors
Dynasore was obtained from Sigma Aldrich 
(Germany), caspase 3/7 inhibitor Z-Asp(OMe)-Glu(OMe)-
Val-DL-Asp(OMe)-fluoromethylketone (Z-DEVD-
FMK) and caspase-8 inhibitor Z-Ile-Glu(OMe)-Thr-DL-
Asp(OMe)-fluoromethylketone (Z-IETD-FMK) were 
obtained from Bachem (Switzerland). The Apoptosis 
(Annexin V/propidium iodide) kit was obtained from 
Roche and protein G microbeads were obtained from 
Miltenyi Biotech. Exogenous caspase-3 and -7 were 
obtained from Biomol (Germany).
Antibodies
The goat anti-actin antibody (C11), mouse anti-
FAS (CD95) antibody (C20) and rabbit anti-Rab4A 
antibody (D20), mouse anti-caspase-3 antibody (E8), 
Oncotarget15www.impactjournals.com/oncotarget
mouse anti-caspase-7 antibody (CSP03) were obtained 
from Santa Cruz Biotechnology. Rabbit anti-caspase-7 
antibody (E22), rabbit anti-caspase-3 (E61), rabbit anti-
caspase-8 antibody (E7), mouse anti-CTSD antibody 
(CTD-19), rabbit anti-A-SMase antibody (ab83354) and 
mouse anti-A-SMase antibody (ab74281) were obtained 
from Abcam. Rabbit anti-cleaved caspase-8 antibody 
(18C8), rabbit anti-caspase-3 antibody (8G10), rabbit 
anti-cleaved caspase-3 antibody (9661) and rabbit anti-
cleaved caspase-7 antibody (9491), rabbit anti-clathrin 
heavy chain (D3C6), rabbit anti-A-SMase antibody (3687) 
and rabbit anti-FADD antibody (2782) were obtained from 
Cell Signaling. The mouse anti-M2-Flag antibody (F1804) 
and rabbit anti-Flag (SIG1-25) were obtained from Sigma 
Aldrich. Rabbit anti-Vti1b (164002) was obtained from 
Synaptic Systems, rabbit anti-GFP antibody (A11122) 
was obtained from Invitrogen and HRP-conjugated mouse 
anti-GFP was obtained from Miltenyi Biotech. Rabbit 
polyclonal anti-A-SMase antibody was generated by 
Areta International s.r.l. (Gerenzano, Italy). The secondary 
antibodies Alexa Fluor 488 labelled anti-mouse IgG 
antibody (A21202), Alexa Fluor 555 labelled anti-mouse 
IgG antibody (A21422) and the Alexa Fluor 555 labelled 
anti-rabbit IgG antibody (A31572) were obtained from 
Invitrogen/Molecular Probes. HRP conjugated donkey 
anti-goat antibody (705-035-003), HRP conjugated rabbit 
anti-mouse antibody (315-035-045) and HRP conjugated 
goat anti-rabbit antibody (111-035-045) were from 
Dianova and HRP conjugated mouse anti-rabbit light 
chain antibody (MAB201P) was obtained from Millipore.
Cell culture
Human SKW6.4, HuT78, HeLa and HEK293 were 
purchased from ATCC. HeLa cells stably overexpressing 
EGFP-A-SMase were described before. HeLa, MEF and 
HEK 293T cells were maintained in DMEM+HEPES 
culture medium (Life Technologies) and HuT78 and 
SKW6.4 cells were maintained in RPMI 1640 medium 
(Life Technologies). Both media were supplemented with 
10% fetal calf serum, 10 mM glutamine, and 0.1 mg/ml 
gentamycin.
Expression and purification of CD95 
ligand (CD95L)
HEK 293T cells were transfected with a plasmid 
coding for Strep-, Fc- and FLAG-tagged CD95L (SFF-
CD95L), by electroporation, transferred into Gibco 
®FreeStyle TM 293 medium and cultivated for 2 days. 
The supernatant was collected and cells were again 
incubated for 2 days adding 1 mg/ml G418 (Biochrom). 
The collected supernatants were applied onto a protein 
G column (GE Healthcare), washed with 20 mM Na2PO4 
pH7,0 and the bound protein was eluted using 0.1 M 
glycine pH 2.7. The eluate was neutralized using 1 M Tris-
HCl pH 9.0. Purity and activity of the CD95L was tested 
by Western blotting and apoptosis assay.
Preparation of cell lysates
Cells were lysed with homogenisation buffer 
(40 mM HEPES pH 7.4; 150 mM KCl; 0.2% NP40) 
by freezing and thawing of the samples. The cells were 
resuspended using a syringe and a 21G needle. The lysate 
was centrifuged for 10 min at 20,000 x g and 4°C. The 
supernatant was used for BCA protein determination.
Immunoprecipitation
Immunoprecipitation of endogenous A-SMase, 
caspase-3, caspase-7 or cleaved caspase-7 was performed 
using 1,8 x 107 HeLa cells cooled on ice for 30 min 
followed by incubation of 100 ng/mL CD95L for 1 hour 
on ice. Temperature shift to 37°C for indicated time 
points was stopped by addition of 1 mL ice cold PBS 
and immediately centrifugation at 300 x g for 5 min at 
4°C. Cell lysates were prepared as described above. 
Protein G coupled antibodies were added and the mixture 
was incubated under rotation for 1 hour at 4°C. Lysate 
was loaded onto a pre-equilibrated μMacs column 
(Miltenyi Biotech), washed with homogenization buffer 
and the precipitated protein was eluted according to the 
manufacturers description.
Immunoprecipitation of EGFP-tagged A-SMase 
was performed as previously described (Edelmann 
et al, 2011) followed by incubation with 50 units of 
exogenous caspase-3 or caspase-7 at 37°C for 15 min. 10 
μl of the reaction mixture was used for A-SMase activity 
determination.
A-SMase activity assay
Activity of A-SMase in cell lysates, CD95-
receptosomes or immunoprecipitated protein was 
measured using N-methyl-[14C]-sphingomyelin (0.5 μCi/
ml, 0.55 Ci/mmol, Perkin Elmer) as substrate in 250 mM 
Na-acetate pH 5.0, 1 mM EDTA, 0.1% Triton X-100. 5-12 
μg of protein was incubated with the substrate for 2 h at 
37°C in a total volume of 150 μl. The reaction mixture 
was extracted using 750 μl chloroform/methanol (2:1) 
and 250 μl H2O. Radioactivity of enzymatically liberated 
radioactive phosphorylcholine in a 250μl aliquot of the 
aqueous phase was measured in a beta-counter.
Western blot analysis
Cells were lysed as described above and proteins 
were separated on 10 to 15% SDS-PAGE. Immunoblotting 
was performed using one of the primary antibodies 
indicated above and secondary antibody horseradish 
peroxidase conjugates. Blots were developed using the 
ECL detection reagent (GE Healthcare).
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Preparation and analysis of magnetic CD95 
containing membrane fractions
Pellets of 1.5 x 108 cells were incubated on ice for 30 
min followed by addition of 500 ng of Fc-tagged CD95L 
and 40 μl protein-G microbeads (Miltenyi Biotech). The 
reaction mixture was incubated for 1 hour on ice, washed 
twice with ice-cold PBS and pelleted by centrifugation 
at 100 x g for 10 min at 4°C. Formation of magnetically 
labelled CD95-receptosomes was achieved by incubation 
of cells at 37°C for various times as indicated in the 
figure legends. Subsequently, cells were homogenized by 
sonication in a 0.25 M sucrose buffer, supplemented with 
15 mM HEPES pH 7.4, 0.5 mM MgCl2 and the Complete® 
protease inhibitor cocktail (Roche) at 4°C. A post-nuclear 
supernatant was applied for magnetic separation of CD95-
receptosomes in a high-gradient magnetic field generated 
in a custom-built free-flow magnetic chamber (Tchikov 
and Schütze, 2008). Magnetic fractions were separated by 
SDS-PAGE and analyzed by Western blot, or were used 
directly for A-SMase activity assays.
Translocation experiments
1 x 106 cells were incubated in serum-free medium 
for 30 min on ice followed by 1 h incubation with 100 ng/
ml CD95L. Temperature shift was performed according 
to the figure legend and stopped using ice-cold RPMI 
medium. Cells were incubated with anti-A-SMase 
antibody (Areta International s.r.l. (Gerenzano, Italy) for 
1 h on ice, washed and incubated with the Alexa Fluor 
555 conjugated anti-rabbit antibody for 1 h. After washing 
with PBS, translocation of A-SMase was analyzed using 
FACS-Calibur (BD) and Cell-Quest 3.3 software.
Apoptosis assay
5 x 105 cells were seeded in six-well plates; 
pretreated with or without 80 μM Dynasore for 30 min and 
stimulated with 100 ng/ml CD95L for 6 hours. The cells 
were harvested and washed once with PBS and centrifuged 
5 min at 200 x g. The cell pellet was resuspended in 
Annexin-V-FLOUS labelling solution containing 
Annexin V and propidium iodide (PI) (according to the 
manufacturer’s instructions) and incubated for 10-15 min 
at room temperature. Stained cells were analyzed using 
the FACS-Calibur (BD) and the Cell-Quest 3.3 software.
Confocal microscopy
5 x 105 cells were incubated for 30 min at 37°C on 
adhesions slides (Squarix, Germany) with or without the 
inhibitors Dynasore (80 μM) or IETD (50 μM) followed 
by 30 min incubation on ice. When incubating the cells 
with inhibitors, all following steps were performed in the 
present of the inhibitor. Adherent cells were incubated 
with 100 ng/ml CD95L for 1 h on ice, washed with PBS 
and incubated at 37°C as indicated in the figure legends. 
Internalization was blocked by washing once with PBS 
followed by fixation of the cells with 4% PFA for 30 min. 
Cells were permeabilised with PBS supplemented with 
0.2% BSA and 0.1% Saponin. Co-localization of CD95L 
with A-SMase, CTSD; Vti1b, Rab4A, caspase-3, cleaved 
caspase-3, caspase-7 and cleaved caspase-7, respectively 
was analyzed. Anti-M2 Flag antibody (mouse or rabbit) in 
combination with the other primary antibodies (A-SMase, 
CTSD, Vti1b, Rab4A, caspase-3, cleaved caspase-3, 
caspase-7 and cleaved caspase-7) were incubated for 1 h 
at RT followed by secondary Alexa Fluor 488 conjugated 
anti-mouse secondary antibody and Alexa Fluor 555 
conjugated anti-rabbit secondary antibody as indicated in 
the figure legends.
Co-localization of A-SMase and caspase-3 or 
caspase-7 was analyzed by incubation of rabbit anti-A-
SMase antibody with mouse-anti-caspase-3 or caspase-7 
antibody followed by incubation of secondary Alexa Fluor 
488 conjugated anti-mouse secondary antibody and Alexa 
Fluor 555 conjugated anti-rabbit secondary antibody.
Cells were mounted with ProLong Gold Dapi 
mounting medium (Invitrogen) and visualized using 
a Zeiss LSM 510 confocal laser scanning microscope 
equipped with an Axiovert 100 M (Carl Zeiss, Jena, 
Germany).
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